CD8A and nonpapillary renal cell carcinoma: Modulation of the exhausted CD8+ T cell phenotype through inhibition of these receptors (such as PD-1 and CTLA-4 blockade) is the basis for ICI therapy and is the current first line systemic therapy for metastatic and adjuvant high risk ccRCC.